Aimmune Therapeutics Inc diskutieren

Überkauft

Gut gelaufen die letzte Zeit heute finaler Anstieg. Mit Kursrückgang muß gerechnet werden.

marge stimmt der Outperform-Einschätzung der institutionellen Analysten zu

marge stimmt am 20.11.2017 der Outperform-Einschätzung der institutionellen Analysten  zu.

• Aimmune Therapeutics (NASDAQ:AIMT) initiated with Buy rating and $60 (71% upside) price target by Roth Capital.

Erdnuss-Allergie

Februar 2018 2018.02.28

„Wir freuen uns auf weitere Fortschritte im Jahr 2018 zu erreichen, vor allem durch die Ergebnisse unserer Zulassungsstudie Phase PALISADE 3 auf der AR101 im Februar teilen“ , sagte Dr. Dilly. „Wir hoffen , dass wir Daten sehen , die stark die letzten Schritte in Richtung auf eine tragfähige Behandlung für Erdnuss - Allergie unterstützen, und wir freuen uns darauf , unser Know - how , um Programme für zusätzliche Allergene zu Anwendung.“

Aimmune Therapeutics achieves primary endpoint of phase 3 study treating patients with peanut allergy.

The data from the phase 3 trial using AR101 to treat peanut allergy is outstanding, and had met its specified endpoint necessary to be able be filed for FDA approval. Considering the medical need for patients who have a peanut allergy, I believe that Aimmune will not have a huge hurdle to cross in terms of receiving approval from the FDA. The reason is because AR101 could become the first oral treatment for those who have peanut allergy. This would be a huge milestone for Aimmune, because its pipeline is devoted to developing treatments for a host of different types of food allergies. Other allergy treatments being explored are those with egg allergy and walnut allergy. The goal for all these treatments is to reduce the amount of sensitivity one experiences when they come into contact with a food allergy. There is still a lot of risk involved with this stock. There is still a risk that the FDA might feel that the data is not adequate enough for approval of AR101. That means that this approval is not guaranteed to happen. Considering that the other programs in the pipeline are still in the pre-IND

stage, that makes the AR101 asset that much more important All is riding on the AR101 treatment, therefore all should be aware of the risk of taking a position into Aimmune Therapeutics. Having said that Aimmune is a good buy.

tamam stimmt am 22.02.2018 der Buy-Einschätzung der institutionellen Analysten mit dem Kursziel 55.5$ zu.

stratec stimmt der Buy-Einschätzung von tamam zu

stratec stimmt am 18.05.2018 der Buy-Einschätzung von tamam mit dem Kursziel 55,5$ zu.
Überschrift: Aimmune Therapeutics achieves primary endpoint of phase 3 study treating patients with peanut allergy.

Up

34$?!

Secteur Recherche biotechnologique et médicale Agenda 02/06 | 12:32 Présentation

Aimmune Therapeutics, Inc. est une société biopharmaceutique au stade clinique qui développe une approche thérapeutique, y compris le développement de produits candidats, pour le traitement des allergies aux arachides et autres allergies alimentaires. L'approche thérapeutique de la Société, qu'elle appelle l'immunothérapie par désensibilisation orale caractérisée (CODIT), est un système conçu pour désensibiliser les patients aux allergènes alimentaires en utilisant des produits biologiques caractérisés, des protocoles thérapeutiques définis et des services de soutien. Le principal produit candidat CODIT de la Société, AR101, est un produit biologique de recherche pour le traitement des patients allergiques aux arachides. La Société a amorcé l'étude PALISADE (étude d'immunothérapie orale contre l'allergie aux arachides sur l'AR101 pour la désensibilisation des enfants et des adultes), son essai clinique de phase III sur l'AR101. La Société est en train d'évaluer d'autres formulaires de livraison pour AR101 pour la phase de maintenance.

Nombre d'employés

: 131 personnes.

Aimmune Therapeutics achieves primary endpoint of phase 3 study treating patients with peanut allergy.

The data from the phase 3 trial using AR101 to treat peanut allergy is outstanding, and had met its specified endpoint necessary to be able be filed for FDA approval. Considering the medical need for patients who have a peanut allergy, I believe that Aimmune will not have a huge hurdle to cross in terms of receiving approval from the FDA. The reason is because AR101 could become the first oral treatment for those who have peanut allergy. This would be a huge milestone for Aimmune, because its pipeline is devoted to developing treatments for a host of different types of food allergies. Other allergy treatments being explored are those with egg allergy and walnut allergy. The goal for all these treatments is to reduce the amount of sensitivity one experiences when they come into contact with a food allergy. There is still a lot of risk involved with this stock. There is still a risk that the FDA might feel that the data is not adequate enough for approval of AR101. That means that this approval is not guaranteed to happen. Considering that the other programs in the pipeline are still in the pre-IND

stage, that makes the AR101 asset that much more important All is riding on the AR101 treatment, therefore all should be aware of the risk of taking a position into Aimmune Therapeutics. Having said that Aimmune is a good buy.

Ergebnisse

gut?